Taking people in United StatesNo phase

Evaluating a home skin device for atopic dermatitis flares

Studies a home skin-measuring device in people with atopic dermatitis over 90 days.

Key facts

Who runs it: Castle Biosciences Incorporated
Where: Caledonia, Columbus, Henderson, Las Vegas, Lee's Summit, Longview, Los Angeles, Missouri City, Morgantown, New York, Norfolk, Phoenix, Portsmouth, Rockville, South Jordan, and Tampa, United StatesSee the 16 sites
Trial code: NCT07645820
Registry title: Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Status: Recruiting
People taking part: 450 people, planned
Started: 4 Jun 2026
Expected to end: 31 Dec 2027
Type of study: Observational
Treatments tested: Nevisense electrical impedance spectroscopy
Record updated: 9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 to 89 with atopic dermatitis (eczema) who had a flare in the past 2 months. They use a skin-measuring device at home for about 90 days.

Age: 12 to 89 years
Sex: All sexes can join.
Disease stage: Diagnosed atopic dermatitis (eczema) with at least one flare in the past 2 months.
Earlier treatment: If on systemic treatment for atopic dermatitis, the same treatment for at least 3 months, with no change planned during the study.

Main reasons for not taking part

Cannot avoid creams, lotions, ointments or soap on measurement areas for 6 hours before measurements
No usable skin areas for study measurements
Another skin condition that may affect study assessments
Pregnancy

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

Participants may be eligible if they:
Are 12 to 89 years old
Have been diagnosed with atopic dermatitis (eczema)
Have had at least one atopic dermatitis flare within the past 2 months
Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits
If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study

Who cannot take part

Have another skin condition that may affect study assessments
Participants may not be eligible if they:
Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements
Do not have suitable skin areas for study measurements
Are pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 12 and 89 years old?

Where in United States

Derm Research Institute, PLCCaledonia, United StatesContact: Kristi Hawley, DO (principal investigator)Taking people
AMR Clinical - Columbus, OHColumbus, United StatesContact: Benjamin Bogucki, MD (principal investigator)Taking people
Advanced Dermatology and Cosmetic Surgery - HendersonHenderson, United StatesContact: Grace (Kim) Dowty, DO, FAOCD, FAAD (principal investigator)Taking people
Las Vegas DermatologyLas Vegas, United StatesContact: David Cotter, MD, PhD (principal investigator)Taking people
U.S. Dermatology Partners Lee's SummitLee's Summit, United StatesContact: Mark Fleischman, MD, FAAD (principal investigator)Taking people
DCOL Center for Clinical ResearchLongview, United StatesContact: Blake Robbins, DO (principal investigator)Taking people
James Y. Wang MD, IncLos Angeles, United StatesContact: James Y Wang, MD (principal investigator)Taking people
Harrison DermatologyMissouri City, United StatesContact: Harrison Nguyen, MD, MBA, MPH, DTM&H FAAD (principal investigator)Taking people
West Virginia Research InstituteMorgantown, United StatesContact: Rola Gharib, MD (principal investigator)Taking people
The Skin Center Dermatology GroupNew York, United StatesContact: Peter Friedman, M.D., Ph.D., FAAD (principal investigator)Taking people
Virginia Clinical Research, Inc.Norfolk, United StatesContact: Robert Pariser, MD (principal investigator)Taking people
U.S. Dermatology PartnersPhoenix, United StatesContact: Margaret Kessler, MD (principal investigator)Taking people
StracSkin, PLLCPortsmouth, United StatesContact: Abel Jarell, MD, FAAD (principal investigator)Taking people
U.S. Dermatology Partners RockvilleRockville, United StatesContact: Benjamin Lockshin, MD, FAAD (principal investigator)Taking people
Jordan Valley DermatologySouth Jordan, United StatesContact: Douglass Forsha, MD (principal investigator)Taking people
True Blue Clinical ResearchTampa, United StatesContact: Stephen Lockwood, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.